25
Jun
2026
Cynosure Lutronic held the Cynosure Lutronic Academy Korea at Chebit Anniversary, Sevit Island, Seocho-gu, Seoul on the 13th, sharing XERF’s clinical value and global utilization strategies with healthcare professionals. (Source: Cynosure Lutronic)
[June 24, 2026] Cynosure Lutronic, a global medical aesthetics company headquartered in the United States, announced the successful conclusion of the “Cynosure Lutronic Academy Korea” (hereinafter “the Conference”) held on the 13th, where the latest clinical value and global utilization strategies of XERF were shared with domestic healthcare professionals.
The conference was held under the theme “XERF: Full Face Custom Design RF,” and was organized to share the latest clinical experiences and case studies involving XERF. The event took place at Chebit Anniversary, Sevit Island, Seocho-gu, Seoul, with over 1,400 healthcare professionals participating both on- and offline.
XERF is the next-generation radiofrequency (RF) medical device that Cynosure Lutronic introduced as its first product following the merger. It adopts a “dual monopolar” approach, adding a 2MHz frequency to the 6.78MHz frequency used by conventional RF devices. Energy delivery depth can be adjusted across three levels, enabling customized treatments. The device features “Wave Fit Pulse” and an “ICD Cooling System,” allowing procedures to be performed without anesthesia.
Han Seon-ho, President of Commercial Operations for Korea and Japan, presents the achievements and future goals of XERF at the Cynosure Lutronic Academy Korea held in Seocho-gu, Seoul on the 13th. (Source: Cynosure Lutronic)
At the conference, Han Seon-ho, President of Commercial Operations for Korea and Japan, stated: “XERF has rapidly established its presence in the global market, achieving 2,000 installations worldwide in a short period since its launch. We hope this event serves as an opportunity to actively share XERF’s clinical value and hands-on experience, and to explore the next direction of growth together with healthcare professionals.”
A live hands-on seminar followed at the Cynosure Lutronic affiliated clinic, recently opened in Gangnam-gu, Seoul. Dr. Park Tae-oh of Relive Clinic demonstrated a periorbital (eye area) treatment procedure, which was streamed live to attendees.
Dr. Jeon Su-il of Jeon Su-il Dermatology Clinic then presented XERF through the concept of “Structural RF” — a framework that considers the full skin layer structure — and outlined clinical application strategies tailored to anatomical structure and site-specific characteristics. Dr. Kim Ki-tae of Taesung Plastic Surgery Clinic highlighted “Total Energy Delivery” as a key factor influencing treatment outcomes, and explained the “100kJ High-Energy Protocol,” which involves delivering an optimal cumulative energy level alongside pain management.
Panel discussion participants and Cynosure Lutronic representatives pose for a commemorative photo at the Cynosure Lutronic Academy Korea held in Seocho-gu, Seoul on the 13th. (Source: Cynosure Lutronic)
The final segment, a panel discussion, was co-chaired by Dr. Park Jae-woo of BIO Plastic Surgery Clinic and Professor Kim Won-seok, a dermatologist at Kangbuk Samsung Hospital. Under their moderation, attendees shared their clinical experiences with XERF and treatment insights, bringing the event to a close.
About Cynosure Lutronic
Cynosure Lutronic provides medical solutions to healthcare professionals and patients worldwide through advanced laser and radiofrequency systems. In 2024, the company announced the launch of “Cynosure Lutronic” through the merger of U.S. and Korean medical device brands “Cynosure” and “Lutronic.” Backed by superior technology and a global network, the company is expected to grow into a world-class enterprise beyond the U.S. and Korea.
In particular, in April 2024, Cynosure Lutronic launched XERF — a monopolar RF medical device — as its first product in the Korean RF device market following the merger announcement. The company also offers a diverse portfolio of energy-based medical devices including DermaV, CLARITY II, HOLLYWOOD SPECTRA, and PicosurePro. Through continuous R&D investment, the company is committed to advancing the global medical device market.